irinotecan has been researched along with Hemolysis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gholami, L; Jaafari, MR; Mahmoudi, A; Malaekeh-Nikouei, B; Ramezanian, N | 1 |
| Bozzato, E; Lopes, A; Papavasileiou, M; Préat, V; Tsakiris, N; Vigneron, AM | 1 |
2 other study(ies) available for irinotecan and Hemolysis
| Article | Year |
|---|---|
BR2 and CyLoP1 enhance in-vivo SN38 delivery using pegylated PAMAM dendrimers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Dendrimers; Drug Carriers; Drug Liberation; Erythrocytes; Female; Hemolysis; Humans; Irinotecan; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Oligopeptides; Polyethylene Glycols; Tissue Distribution | 2019 |
Combinational drug-loaded lipid nanocapsules for the treatment of cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Combinations; Erythrocytes; Female; Hemolysis; Humans; Irinotecan; Lipids; Mice, Inbred BALB C; Nanocapsules; Neoplasms; Phenylurea Compounds; Pyridines | 2019 |